Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance.
Prognostic relevance of serum p53 antibodies was assessed in 96 patients with microscopically proven small cell lung cancer (SCLC). The study group included 67 males and 29 females; mean age 58 years; range 35--86 years; 60 with limited disease (LD), and 36 with extensive disease (ED). The control group consisted of 41 patients with non-malignant diseases. The presence of p53 antibodies was assayed by the immunoenzymatic method (P53 ELISA kit, PharmaCell, France). Antibodies were present in 26 SCLC cases (27%); 15 (25%) in LD and 11 (31%) in ED. Antibodies were also found in one out of 41 control subjects (2%). There was no correlation between the level of antibodies and clinical characteristics of SCLC patients including age, gender and extent of disease. The median follow-up for the entire group was 30 months (range: 11--39 months). By the time of analysis, 78 patients (82%) had deceased. Median survival in SCLC patients with and without antibodies was 42 and 39 weeks, respectively (log rank, P=0.81). These results indicate the lack of clinical relevance of serum p53 antibodies in SCLC.
Jassem
E
E
Department of Pneumonology, Medical University of Gdańsk, 7 Debinki St, 80-211, Gdańsk, Poland.
Bigda
J
J
Dziadziuszko
R
R
Schlichtholz
B
B
Le Roux
D
D
Grodzki
T
T
Rzyman
W
W
Konopa
K
K
Poberezna
M
M
Dobrzańska
Z
Z
Skokowski
J
J
Soussi
T
T
Jassem
J
J
D000328:Adult; D000368:Aged; D000912:Antibodies, Neoplasm / Q000032:analysis*; D018288:Carcinoma, Small Cell / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D000912:Antibodies, Neoplasm; D016159:Tumor Suppressor Protein p53